Donald Betah
ACELYRIN Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Donald Betah as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:25 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05384249 · Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitisACELYRIN Inc. · terminated · Uveitis · study director
- Ph2NCT05355805 · Hidradenitis Suppurativa Phase 2b Study of IzokibepACELYRIN Inc. · completed · Hidradenitis Suppurativa · study director
- Ph2NCT04706741 · A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior UveitisACELYRIN Inc. · completed · Uveitis · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:25 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:25 UTC. The ranking covers the 200 most relevant of 7 PubMed records, and a shared surname and initials can bring in a namesake. All 7 on PubMed
- Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results From the FRAME Clinical Trial.J Bone Miner Res · 202248 citationsRCR 4.7
- Romosozumab improves microarchitecture as assessed by tissue thickness-adjusted trabecular bone score in postmenopausal women with osteoporosis.J Bone Miner Res · 202521 citationsRCR 7.8
- Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extension.J Bone Miner Res · 202419 citationsRCR 3.7
- 3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate.J Bone Miner Res · 202417 citationsRCR 4.2
- Reconstruction of remodeling units reveals positive effects after 2 and 12 months of romosozumab treatment.J Bone Miner Res · 202414 citationsRCR 2.4
- Romosozumab Improves Tissue Thickness-Adjusted Trabecular Bone Score in Women With Osteoporosis and Diabetes.J Clin Endocrinol Metab · 20254 citationsRCR 1.8